Dr. Têtu is professor emeritus at the Faculty of Medicine of Laval University and a regular researcher in the Oncology axis of the CHU Research Centre of Quebec since 1986. Since the beginning of his career, in addition to his clinical practice and research activities, particularly as a FRSQ senior clinical researcher grant holder, he held various executive positions such as head of the Division of Pathology in the Department of Molecular Biology, Medical Biochemistry and Pathology, Director of the Clinician-Scientist Residency Program and Graduate Program in Clinical Epidemiology, Medical Director of RUIS Telepathology Project at Laval University, Chief of Pathology Services at CHUQ and CHA, Assistant Director of Clinical Research at CHUQ Research Centre, Chair of the Advisory Committee on Anatomical Pathology at the Quebec Cancer Board (Ministry of Health) and Chair of the membership committee of the Canadian Association of Pathologists.
His research themes are:
Clinical validation of new tumor markers
His studies aim to validate tumor markers identified as potentially interesting for predicting the evolution of cancers. These studies are applied to cohorts of patients using histopathological approaches, and therefore involve expertise in cellular and molecular biology, pathology and epidemiology. Several studies use samples from a tumor bank that he has been developing for over 20 years.
Studying the benefits and challenges of using telepathology
Telepathology is a technology that Dr. Têtu has helped to introduce in eastern Quebec, and allows the pathologist to establish remote diagnostics, mainly in oncology. Collaborations with experts in information technology assessment, applied in telemedicine, help identify the socio-political, organizational, clinical, professional, legal and technological benefits and challenges related to the introduction of telepathology.
1050, chemin Sainte-Foy
Service d'anatomopathologie et de cytologie
Canada G1S 4L8
Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.Journal Article
J Urol, 162 (6), pp. 2024-8, 1999, ISSN: 0022-5347.
Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.Journal Article
Hum Pathol, 30 (11), pp. 1350-5, 1999, ISSN: 0046-8177.
The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.Journal Article
Br J Urol, 81 (5), pp. 692-8, 1998, ISSN: 0007-1331.
Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors.Journal Article
J Urol, 157 (5), pp. 1660-4, 1997, ISSN: 0022-5347.
Neoadjuvant hormonal therapy: the Canadian experience.Journal Article
Urology, 49 (3A Suppl), pp. 56-64, 1997, ISSN: 0090-4295.
Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer.Journal Article
Hum Pathol, 27 (9), pp. 922-6, 1996, ISSN: 0046-8177.
Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer.Journal Article
J Urol, 155 (5), pp. 1784-8, 1996, ISSN: 0022-5347.
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.Journal Article
Prostate, 28 (4), pp. 227-31, 1996, ISSN: 0270-4137.
Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder.Journal Article
Clin Cancer Res, 1 (10), pp. 1195-202, 1995, ISSN: 1078-0432.
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.Journal Article
Cancer Surv, 23 , pp. 149-56, 1995, ISSN: 0261-2429.